Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study

Abstract Objective To compare the effectiveness of discontinuing treatment with amoxicillin after three days or eight days in adults admitted to hospital with mild to moderate-severe community acquired pneumonia who substantially improved after an initial three days' treatment. Design Randomised, double blind, placebo controlled non-inferiority trial. Setting Nine secondary and tertiary care hospitals in the Netherlands. Participants Adults with mild to moderate-severe community acquired pneumonia (pneumonia severity index score ≤ 110). Interventions Patients who had substantially improved after three days' treatment with intravenous amoxicillin were randomly assigned to oral amoxicillin (n = 63) or placebo (n = 56) three times daily for five days. Main outcome measures The primary outcome measure was the clinical success rate at day 10. Secondary outcome measures were the clinical success rate at day 28, symptom resolution, radiological success rates at days 10 and 28, and adverse events. Results Baseline characteristics were comparable, with the exception of symptom severity, which was worse in the three day treatment group. In the three day and eight day treatment groups the clinical success rate at day 10 was 93% for both (difference 0.1%, 95% confidence interval − 9% to 10%) and at day 28 was 90% compared with 88% (difference 2.0%, − 9% to 15%). Both groups had similar resolution of symptoms. Radiological success rates were 86% compared with 83% at day 10 (difference 3%, − 10% to 16%) and 86% compared with 79% at day 28 (difference 6%, − 7% to 20%). Six patients (11%) in the placebo group and 13 patients (21%) in the active treatment group reported adverse events (P = 0.1). Conclusions Discontinuing amoxicillin treatment after three days is not inferior to discontinuing it after eight days in adults admitted to hospital with mild to moderate-severe community acquired pneumonia who substantially improved after an initial three days' treatment.

[1]  D. Snydman Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study , 2006, BMJ : British Medical Journal.

[2]  J. Hermans,et al.  Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia , 1995, European Journal of Clinical Microbiology and Infectious Diseases.

[3]  M. Pichichero,et al.  Metaanalysis of Short Course Antibiotic Treatment for Group A Streptococcal Tonsillopharyngitis , 2005, The Pediatric infectious disease journal.

[4]  M. Bonten,et al.  Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia. , 2005, The Netherlands journal of medicine.

[5]  H. Goossens,et al.  Outpatient antibiotic use in Europe and association with resistance: a cross-national database study , 2005, The Lancet.

[6]  J. Rodenhiser,et al.  Competing interests: None declared. , 2005 .

[7]  P. Bossuyt,et al.  Development and validation of a short questionnaire in community acquired pneumonia , 2004, Thorax.

[8]  G. Agarwal,et al.  Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial , 2004, BMJ : British Medical Journal.

[9]  Leon G Smith,et al.  High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  L. Hagberg,et al.  Efficacy and Tolerability of Once-Daily Telithromycin Compared with High-Dose Amoxicillin for Treatment of Community-Acquired Pneumonia , 2002, Infection.

[11]  Norbert Vetter,et al.  A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. , 2002, Clinical therapeutics.

[12]  Pakistan Multicentre Amoxicillin Short Course Therapy pneum group Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial , 2002, The Lancet.

[13]  P. Nikolaides,et al.  Randomized Controlled Trial of Sequential Intravenous (i.v.) and Oral Moxifloxacin Compared with Sequential i.v. and Oral Co-Amoxiclav with or without Clarithromycin in Patients with Community-Acquired Pneumonia Requiring Initial Parenteral Treatment , 2002, Antimicrobial Agents and Chemotherapy.

[14]  G. Woods,et al.  A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  O. Cars,et al.  The Relationship between Antimicrobial Use and Antimicrobial Resistance in Europe , 2002, Emerging Infectious Diseases.

[16]  O. Cars,et al.  A European study on the relationship between antimicrobial use and antimicrobial resistance. , 2002, Emerging infectious diseases.

[17]  W. Lim,et al.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults , 2001, Thorax.

[18]  C Peña,et al.  Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. , 2001, JAMA.

[19]  J. Friend Do smoking parents seek the best advice for their asthmatic children? , 2001, Thorax.

[20]  M. Fine,et al.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.

[21]  P. Arvis,et al.  Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. , 2001, Chest.

[22]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  D. Felmingham,et al.  The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. , 2000, The Journal of antimicrobial chemotherapy.

[24]  O. Muller,et al.  Randomized, Multicentre Study of the Efficacy and Tolerance of Azithromycin versus Clarithromycin in the Treatment of Adults with Mild to Moderate Community-Acquired Pneumonia , 1998, European Journal of Clinical Microbiology and Infectious Diseases.

[25]  Claude Carbón,et al.  Regulating the use of antibiotics in the community , 1998, BMJ.

[26]  G. Gottlieb,et al.  Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  B. Balkau,et al.  Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. , 1998, JAMA.

[28]  P Huovinen,et al.  The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. , 1997, The New England journal of medicine.

[29]  M. Fine,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[30]  M. Rozenberg-Arska,et al.  A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. , 1997, International journal of antimicrobial agents.

[31]  J. Klein,et al.  Evaluation of New Anti-Infective Drugs for the Treatment of Respiratory Tract Infections , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  G. H. Ree,et al.  Treatment of lobar pneumonia in Papua New Guinea: short course chemotherapy with penicillin or chloramphenicol. , 1983, The Journal of infection.

[33]  A. Wicks,et al.  One-day treatment for lobar pneumonia , 1970, Thorax.